Kiniksa Pharmaceuticals, Ltd. Reports Q3 Loss, Tops Revenue Estimates
AFMD Stock | USD 2.62 0.02 0.76% |
About 60% of Affimed NV's investor base is looking to short. The analysis of the overall investor sentiment regarding Affimed NV suggests that many traders are alarmed. The current market sentiment, together with Affimed NV's historical and current headlines, can help investors time the market. In addition, many technical investors use Affimed NV stock news signals to limit their universe of possible portfolio assets.
Affimed |
Kiniksa Pharmaceuticals delivered earnings and revenue surprises of -1,700 percent and 1.77, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock
Read at zacks.com
Affimed NV Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Affimed NV can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Affimed NV Fundamental Analysis
We analyze Affimed NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Affimed NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Affimed NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Affimed NV is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Affimed NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Affimed NV stock to make a market-neutral strategy. Peer analysis of Affimed NV could also be used in its relative valuation, which is a method of valuing Affimed NV by comparing valuation metrics with similar companies.
Peers
Affimed NV Related Equities
AGEN | Agenus | 16.78 | ||||
PIRS | Pieris Pharmaceuticals | 5.27 | ||||
INZY | Inozyme Pharma | 4.46 | ||||
ADAP | Adaptimmune Therapeutics | 3.13 | ||||
DAWN | Day One | 2.85 | ||||
ADCT | ADC Therapeutics | 2.58 | ||||
TERN | Terns Pharmaceuticals | 1.40 | ||||
MREO | Mereo BioPharma | 1.09 | ||||
CRVS | Corvus Pharmaceuticals | 0.11 | ||||
LPTX | Leap Therapeutics | 1.16 | ||||
ELEV | Elevation Oncology | 1.64 | ||||
HEPA | Hepion Pharmaceuticals | 4.35 | ||||
PDSB | PDS Biotechnology | 5.00 | ||||
XFOR | X4 Pharmaceuticals | 8.11 | ||||
APTO | Aptose Biosciences | 20.83 |
Complementary Tools for Affimed Stock analysis
When running Affimed NV's price analysis, check to measure Affimed NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Affimed NV is operating at the current time. Most of Affimed NV's value examination focuses on studying past and present price action to predict the probability of Affimed NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Affimed NV's price. Additionally, you may evaluate how the addition of Affimed NV to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |